KYTX LAWSUIT ALERT: Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Key Takeaways:

• Class action lawsuit filed against Kyverna Therapeutics by Levi & Korsinsky, LLP
• Allegations of false statements and concealed information during February 2024 IPO
• Investors have until February 7, 2025, to seek lead plaintiff status
• No cost or obligation for investors to participate in the lawsuit
• Law firm has a strong track record in securities litigation

Kyverna Therapeutics Faces Securities Fraud Allegations

Kyverna Therapeutics, Inc., a biotech company listed on the NASDAQ under the ticker KYTX, is confronting a class action securities lawsuit filed by the law firm Levi & Korsinsky, LLP. The lawsuit alleges that the company made false statements and concealed crucial information during its initial public offering (IPO) in February 2024.

Alleged Misstatements During IPO

The complaint asserts that Kyverna Therapeutics and associated parties issued offering documents that contained misleading information. “The filed complaint alleges that defendants made false statements and/or concealed that: (i) the strategy to best accomplish the IPO; (ii) the terms of the IPO, including the price at which Kyverna’s common stock would be sold,” the lawsuit states. These alleged actions are said to have adversely affected investors who purchased or acquired Kyverna common stock pursuant to the IPO.

Impact on Investors

Investors who participated in the IPO or purchased stock traceable to the offering documents may have suffered significant losses due to the alleged securities fraud. The lawsuit seeks to recover these losses on behalf of the affected shareholders. According to the announcement, “This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company’s offering documents issued in connection with its February 2024 initial public offering.”

Deadline for Lead Plaintiff Appointment

Time is of the essence for investors considering legal action. Affected parties have until February 7, 2025, to request that the court appoint them as lead plaintiff in the case. Serving as lead plaintiff is not a requirement to share in any potential recovery. There are no out-of-pocket costs or fees for participating class members. “Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees,” the notice emphasizes.

Levi & Korsinsky’s Track Record

Levi & Korsinsky, LLP brings substantial experience to the case, with over 20 years in securities litigation. The firm has secured “hundreds of millions of dollars for aggrieved shareholders” and boasts a team of more than 70 employees dedicated to representing investors. “Our firm has extensive expertise representing investors in complex securities litigation,” the announcement highlights, underscoring their credibility and commitment.

Next Steps for Affected Investors

Investors who believe they may be affected are encouraged to consider their legal options promptly. For more information, they can contact Joseph E. Levi, Esq. via email at

Investor Advocacy and Corporate Accountability

The unfolding lawsuit against Kyverna Therapeutics underscores the critical importance of transparency and honesty in the corporate sphere, especially during pivotal events like an IPO. As the case progresses, it may have significant implications for the company and its shareholders, highlighting the role of legal action in holding corporations accountable.